| OBSERVATION'S |
Emphasized that the right partner depends on the development stage of the prodt. At the preclinical stage, the manufacture is open to a lot of flexibility. But as the prodt. moves along in development, regulatory restrictions & production costs kick in. Close to launch, the ability of the contract manufacturer to produce the projected demand becomes critical. “Virtual” pharmaceutical companies may be best served by full-service providers. But companies with more in-house capabilities might be better off picking & choosing specific partners for specific projects
|